A urine immunofixation test looks for a monoclonal immunoglobulin protein in urine and identifies its type, especially free kappa or free lambda light chains. It is commonly used with urine protein electrophoresis (UPEP), serum protein electrophoresis, serum immunofixation, and serum free light chains when clinicians are evaluating multiple myeloma, AL amyloidosis, or another monoclonal gammopathy. A monoclonal free light chain detected in urine is traditionally called Bence Jones protein.
Urine immunofixation is usually reported as a pattern—such as no monoclonal protein detected, monoclonal free kappa, monoclonal free lambda, or a monoclonal intact immunoglobulin—not as a “high” or “low” value. A positive result does not automatically mean active multiple myeloma. Monoclonal proteins can occur with MGUS, smoldering myeloma, lymphoplasmacytic disorders, AL amyloidosis, and monoclonal gammopathy of renal significance. The significance depends on the amount and type of protein, blood test results, bone marrow findings, symptoms, imaging, and whether organ damage is present.
- What it detects: monoclonal immunoglobulins or free light chains in urine and their kappa/lambda type.
- Positive free kappa or lambda: confirms a monoclonal urinary light chain pattern, also called Bence Jones proteinuria.
- Negative result: no monoclonal band was detected in that specimen, but a plasma-cell disorder can still be present.
- No universal numeric range: immunofixation is mainly qualitative; UPEP or other assays are used when protein quantity is needed.
- Why it matters: monoclonal light chains can help diagnose plasma-cell disorders and may signal kidney risk when production is high.
Table of Contents
- What urine immunofixation is
- Why the test is ordered
- How urine immunofixation works
- What urine immunofixation results mean
- Myeloma and other causes of a positive result
- Kidney implications of monoclonal light chains
- Urine versus serum tests
- What happens after an abnormal result
What urine immunofixation is
Immunofixation electrophoresis is a laboratory method used to identify the immunoglobulin type of a suspicious protein. Antibodies are made by plasma cells and normally contain heavy chains plus either kappa or lambda light chains. A healthy immune system produces many different antibody molecules, creating a broad polyclonal pattern. A single abnormal plasma-cell or B-cell clone can instead produce a large amount of one identical protein, creating a monoclonal pattern.
In urine, the most important monoclonal proteins are often free light chains. These small kappa or lambda proteins can pass through the kidney’s filters. When one clone produces a large amount, the light chain can appear in urine as Bence Jones protein.
Urine immunofixation is different from quantitative urine free light chain testing. A quantitative assay measures concentrations of kappa and lambda. Immunofixation asks whether a discrete monoclonal protein is present and identifies its immunologic type. It is also different from UPEP, which separates urinary proteins by migration pattern and can quantify a monoclonal component in a properly collected timed sample.
The test is a monoclonal protein test, not a direct tumor-cell test. A positive band proves abnormal clonal protein production more strongly than a nonspecific increase in total urine protein, but it does not by itself establish the disease causing that production.
Why the test is ordered
Urine immunofixation is ordered when the clinician needs to determine whether a suspicious urinary protein is monoclonal. It is often part of the evaluation for plasma-cell disorders and is particularly useful when free light-chain disease or AL amyloidosis is possible.
Common reasons include:
- an M protein or suspicious band on serum or urine electrophoresis;
- an abnormal serum free light chain ratio;
- unexplained kidney impairment or proteinuria;
- anemia, high calcium, bone pain, or lytic lesions suggesting multiple myeloma;
- suspected AL amyloidosis;
- known multiple myeloma requiring characterization or selected response assessment;
- suspected monoclonal gammopathy of renal significance;
- a need to determine whether urinary protein is free kappa, free lambda, or part of an intact immunoglobulin.
The test is rarely useful in isolation. Multiple myeloma evaluation typically combines laboratory, marrow, and imaging evidence. A patient may have a positive urine immunofixation but not meet criteria for active myeloma, while another patient with light-chain myeloma may have an abnormal serum free light chain test even when urine immunofixation is negative.
Urine immunofixation remains especially important in suspected AL amyloidosis, where demonstrating a monoclonal protein with both serum and urine methods improves sensitivity. It is also recommended in the assessment of myeloma-related kidney impairment because the type of urinary protein can help distinguish light-chain injury from predominantly albuminuric kidney disease.
How urine immunofixation works
The laboratory first separates urine proteins by electrophoresis. The separated proteins are then exposed to antisera directed against immunoglobulin heavy and light chains. Where an antigen and its matching antibody meet, the protein is “fixed” into a visible band after processing.
The exact lanes and antisera differ among laboratories. Common targets include gamma, alpha, and mu heavy chains and kappa and lambda light chains. Specialized urine methods may use antisera that are particularly sensitive to free kappa and free lambda chains.
Urine often contains far less protein than serum, so laboratories may concentrate the specimen before immunofixation. Membrane filtration has traditionally been used; newer laboratory studies have evaluated alternative concentration methods and free-light-chain–specific antisera to improve sensitivity.
Spot urine versus 24-hour urine
Urine immunofixation can be performed on a spot sample in some settings, especially when the main question is simply whether a monoclonal band exists. A 24-hour collection is more useful when the clinician also needs to quantify total monoclonal protein excretion.
A complete 24-hour collection starts after discarding the first morning void, then saves every void for the next 24 hours, including the final void at the same time the next morning. Missing a substantial portion of urine can underestimate daily protein excretion, even if immunofixation still detects the monoclonal band.
No fasting is usually needed for urine immunofixation. Hydration affects urine concentration, but patients should generally follow normal fluid intake unless their clinician gives different instructions. The laboratory’s collection and storage directions should be followed exactly.
Urine specimens often need concentration before immunofixation because monoclonal proteins may be present at much lower concentrations than in serum. Laboratories can use filtration or other validated concentration methods to increase the amount of protein applied to the gel. This improves detection but also makes method consistency important. A faint band on one platform should not be compared numerically with a result from a different preparation method, and immunofixation itself is primarily a qualitative identification technique rather than a precise concentration measurement.
A urine result can also disagree with serum testing for biological reasons. Free light chains circulate in blood, pass through the glomerular filter, and are normally reabsorbed and metabolized by proximal tubular cells. When production becomes excessive or tubular handling is impaired, more light chain reaches the urine. A small monoclonal clone may therefore produce an abnormal serum free light-chain ratio before a large amount appears in urine, while significant urinary monoclonal protein can become especially important when kidney injury or heavy light-chain production is present. This is why clinicians usually interpret urine immunofixation together with serum protein electrophoresis, serum immunofixation, serum free light chains, kidney function, and the total amount of urinary protein rather than treating it as a stand-alone test.
What urine immunofixation results mean
The report is usually descriptive rather than numerical. Wording varies, but common patterns include “no monoclonal protein detected,” “monoclonal free kappa light chain,” “monoclonal free lambda light chain,” or an intact immunoglobulin with a particular heavy- and light-chain combination.
A negative urine immunofixation means no monoclonal band was identified in that specimen. It does not fully rule out a plasma-cell disorder. Serum free light chain testing is more sensitive for many light-chain abnormalities because the kidneys reabsorb much of the filtered protein before it appears in urine.
A positive free kappa or free lambda band confirms monoclonal free light-chain excretion. That is the modern laboratory equivalent of identifying Bence Jones protein. The next question is which disorder is producing it and whether it is causing organ injury.
An intact monoclonal immunoglobulin may also appear in urine, particularly when serum concentrations are high or kidney permeability is altered. The report may identify a type such as IgG kappa, although free light chains are often the main urinary finding in myeloma.
| Report wording | General meaning | Typical next question |
|---|---|---|
| No monoclonal protein detected | No discrete clonal band seen | Are serum studies normal too? |
| Monoclonal free kappa | Bence Jones kappa protein present | What is the serum kappa level/ratio and underlying diagnosis? |
| Monoclonal free lambda | Bence Jones lambda protein present | What is the serum lambda level/ratio and underlying diagnosis? |
| Intact monoclonal immunoglobulin | Clonal heavy-and-light-chain protein present in urine | What is the matching serum M protein and disease burden? |
| Faint/restricted band | Possible low-level monoclonal protein | Does repeat testing and serum IFE confirm it? |
“Faint,” “trace,” or “restricted” bands can be challenging. Very low-level monoclonal proteins may be real, but artifacts and oligoclonal immune patterns can complicate interpretation. The laboratory may recommend correlation with serum studies or repeat testing.
Immunofixation does not measure tumor burden directly
A strong band is not a direct count of plasma cells, and a faint band is not automatically harmless. Immunofixation is optimized for identification, not precise quantification. UPEP, serum M-protein measurement, and serum FLC concentration are used to follow measurable disease, depending on what the patient’s clone produces.
Treatment can also change the pattern. After stem-cell transplantation or immunotherapy, small oligoclonal bands may appear during immune reconstitution and can differ from the original myeloma protein. Comparing the heavy- and light-chain type with the patient’s baseline clone helps avoid mistaking a new benign pattern for relapse.
Myeloma and other causes of a positive result
Multiple myeloma is an important cause of monoclonal protein in urine, but it is not the only one. A positive immunofixation result can occur across a spectrum of clonal plasma-cell and B-cell disorders.
Possible diagnoses include:
- MGUS (monoclonal gammopathy of undetermined significance): a clonal protein without myeloma-defining organ damage or high tumor burden;
- smoldering multiple myeloma: a larger clonal plasma-cell burden than MGUS but no myeloma-defining event;
- active multiple myeloma: clonal plasma-cell disease with specific organ-damage or biomarker criteria;
- light-chain myeloma: myeloma producing mainly free kappa or lambda rather than a large intact immunoglobulin;
- AL amyloidosis: a small plasma-cell clone can produce toxic light chains that form amyloid deposits in organs;
- monoclonal gammopathy of renal significance: a clone that may be too small to meet myeloma criteria but produces an immunoglobulin that damages the kidneys;
- selected lymphomas or lymphoplasmacytic disorders that secrete monoclonal immunoglobulins.
This spectrum is why the laboratory cannot label a positive urine band “myeloma” by itself. The diagnosis depends on bone marrow plasma-cell percentage, imaging, blood counts, kidney function, calcium, serum biomarkers, and evidence of tissue or organ involvement.
A related blood immunofixation test is usually performed at the same time because serum and urine can show different aspects of the same clone.
Kidney implications of monoclonal light chains
Monoclonal light chains are important because they can be directly toxic to the kidneys. In light-chain cast nephropathy, extremely high circulating free light chains pass through the glomeruli, interact with proteins in the distal nephron, and form obstructing casts. This can cause rapid acute kidney injury and is a medical urgency in newly diagnosed myeloma.
Other monoclonal proteins damage different parts of the kidney. AL amyloidosis and light-chain deposition disease often affect glomeruli and can cause large amounts of albumin in urine, swelling, and nephrotic syndrome. Some monoclonal gammopathy–related lesions involve complement or specific tubular structures.
For myeloma patients with kidney impairment, international recommendations include serum FLC measurement plus 24-hour urine total protein, electrophoresis, and immunofixation. If the urine is predominantly albumin or the involved serum FLC level is not extremely high, kidney biopsy may be needed to identify the exact lesion rather than assuming cast nephropathy.
A positive urine immunofixation does not prove the monoclonal protein caused the kidney disease. Older adults can have MGUS and unrelated diabetic or vascular kidney disease at the same time. Determining causality may require nephrology assessment and sometimes kidney biopsy.
Urine versus serum tests
Serum free light chains have become central to monoclonal gammopathy screening because they are sensitive, quantitative, and do not depend on a complete 24-hour urine collection. For most screening situations, SPEP, serum immunofixation, and serum FLC together detect most clinically relevant monoclonal gammopathies.
Urine testing still provides information serum cannot fully replace in every situation. It directly demonstrates renal excretion of the monoclonal protein, can quantify 24-hour urinary M protein with UPEP, and remains important in AL amyloidosis and selected response criteria.
A negative urine result with a clearly abnormal serum FLC ratio is therefore not contradictory. The kidney may reabsorb enough light chain to prevent a visible urinary band. Conversely, a urinary monoclonal light chain can be clinically important even when the serum M-spike is small because light-chain disorders may produce little intact immunoglobulin.
The best practice is not to choose one specimen type as universally superior, but to use the combination that answers the clinical question. Screening, renal diagnosis, AL amyloidosis evaluation, and treatment-response monitoring may require different combinations.
What happens after an abnormal result
A new monoclonal band usually leads to a complete monoclonal gammopathy evaluation. This may include serum free kappa and lambda with ratio, SPEP, serum immunofixation, CBC, calcium, creatinine, quantitative urine protein, and imaging for bone disease. A hematologist may recommend bone marrow biopsy if the overall findings suggest a plasma-cell neoplasm.
If kidney function is abnormal or proteinuria is substantial, nephrology involvement may be appropriate. The pattern of albumin versus light-chain protein, serum FLC burden, and clinical course helps determine whether kidney biopsy is needed.
A positive result does not always require treatment. MGUS is usually monitored, while active myeloma, AL amyloidosis with organ involvement, and clinically significant monoclonal kidney disease may require clone-directed therapy. The diagnosis—not the immunofixation band alone—determines treatment.
Prompt assessment is important for rapidly rising creatinine, markedly reduced urine output, severe dehydration, confusion, weakness, new severe bone pain, or other signs of myeloma complications. In suspected light-chain cast nephropathy, reducing free light-chain production quickly can be important for preserving kidney function.
The clearest way to understand a report is to ask: What monoclonal type was found? Is the same clone present in serum? How large is the protein burden? Is there evidence that it is damaging the kidneys, bones, blood counts, or other organs? Those questions turn a laboratory band into a clinically useful diagnosis.
References
- Urine Immunofixation Electrophoresis for Diagnosis of Monoclonal Gammopathy: Evaluation of Methods for Urine Concentration. 2024
- Urine Protein Immunofixation Electrophoresis: Free Light Chain Urine Immunofixation Electrophoresis Is More Sensitive than Conventional Assays for Detecting Monoclonal Light Chains and Could Serve as a Marker of Minimal Residual Disease. 2023
- Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin 2024
- Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management 2024 (Review)
- Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group 2023 (Guideline)
- Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies 2024 (Review)
Disclaimer
This article is for general education and does not replace diagnosis by a hematologist, nephrologist, or laboratory specialist. A positive urine immunofixation identifies a monoclonal protein pattern but cannot by itself determine whether the cause is MGUS, multiple myeloma, AL amyloidosis, or another disorder. Rapidly worsening kidney function or other serious symptoms require prompt medical evaluation.
